3 Stocks This $72 Billion Hedge Fund Recently Bought

Check out which stocks one of the world's most successful hedge funds recently bought and why.

May 21, 2014 at 4:47PM

Chicago-based Citadel Advisors is one of the largest and most successful hedge funds in the world. Money managers like Citadel must reveal their stock maneuvers every quarter in SEC 13F filings. Here are three of Citadel's recent stock purchases.

Bristol-Myers Squibb (NYSE:BMY) grabbed Citadel Advisors' attention this quarter, boosting its total stake to nearly $15 million. The New York-based pharmaceutical company is in the midst of a drawn-out patent cliff. Over the next several years, Bristol will lose patent protection on drugs that currently generate a significant amount of sales. Yet Bristol boasts a strong drug pipeline, particularly in cancer research. The company has invested heavily in nivolumab, a promising drug that will likely deliver an improvement in the way the disease is treated. However, with other drug companies like Merck and Roche also making strides in that area, investors may have become overly optimistic about the revenue Bristol's new compound might generate.

Enthusiasm is reflected in Bristol's valuation: The drugmaker's price-to-earnings ratio of roughly 28 times is a premium to its industry average of less than 25. But so far, that hasn't stopped Citadel from buying Bristol-Myers Squibb's stock.

Citadel owns a nearly $25 million stake in The Coca-Cola Company (NYSE:KO) with over 637,000 shares. Coke's ability to develop new products and reinvent old ones generates stable profits for the company and its shareholders. One of the world's most far-reaching distribution systems serves Coke's mammoth beverage portfolio, including its 17 billion-dollar brands. The cola giant's production techniques are well developed, resulting in high profit margins. Although U.S. soda consumption is declining and Coke has struggled with sluggish soda sales, the company is actively reinventing itself. To jolt sales of its entire product line-up, Coke is exploring alternatives. For example, Coca-Cola and Keurig Green Mountain signed an agreement to develop and roll out Coke's global portfolio of products for use in Green Mountain's upcoming Keurig Cold at-home beverage system. It's unclear whether these machines will boost at-home consumption of Coke products, but the company feels this is an opportunity to grow overall sales. Apparently, Citadel Advisors agrees.

The hedge fund also owns a $31.6 million position in Pfizer (NYSE:PFE). The drug maker has become a huge organization after acquiring many companies over the past several years. These acquisitions benefited Pfizer, but some came with divisions that were unrelated to its core pharmaceutical business. As a result, Pfizer has refocused on its core business by selling or spinning off some non-pharma divisions such as Nutrition and Animal Health. For example, last year the drug maker launched an IPO of a minority stake in Zoetis, once Pfizer's animal health business. Many investors, likely Citadel Advisors included, believe this strategy will allow Pfizer's robust drug pipeline to have a greater impact on company growth and profitability. Despite Lipitor's recent patent expiration, Pfizer boasts a healthy drug pipeline, including therapies for rheumatoid arthritis, stroke prevention, and cancer.

Bristol-Myers Squibb, Coca-Cola, and Pfizer possess forward price-to-earnings ratios of 29, 18, and 13, respectively. By comparison, the P/E ratio of the S&P 500 is currently 18, signaling Coca-Cola may be fairly valued and Pfizer may be undervalued. The Motley Fool CAPS community rates Bristol-Myers Squibb, Coca-Cola, and Pfizer all 4-star (out of 5) stocks. 

Foolish takeaway
Citadel Advisors is feeling bullish on these three companies right now. But don't blindly follow this hedge fund's moves into these stocks with positions of your own. Conduct your own research and formulate your thesis. You'll be a better investor for it.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Nicole Seghetti owns shares of Pfizer. Follow her on Twitter @NicoleSeghetti. The Motley Fool recommends Coca-Cola and Keurig Green Mountain. The Motley Fool has the following options: long January 2016 $37 calls on Coca-Cola and short January 2016 $37 puts on Coca-Cola. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers